Citius Pharmaceuticals (STU:47N0) Moat Score: 4/10 (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:47N0 Citius Pharmaceuticals Inc STU:47N0
25 GF Score
Price €3.29
! 2 Warning Signs
View Full Analysis

What is Citius Pharmaceuticals Moat Score?

Citius Pharmaceuticals STU:47N0 25 Moat Score is 4 as of Aug. 08, 2026. GuruFocus rates STU:47N0 with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 1,393 Biotechnology companies, Citius Pharmaceuticals ranks better than 88.8% on this metric.

Citius Pharmaceuticals has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Citius Pharmaceuticals has Narrow Moat: Citius Pharmaceuticals Inc has a modest moat due to its focus on niche pharmaceutical products and potential intellectual property. However, it faces significant competition and lacks strong brand strength or market leadership.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Citius Pharmaceuticals might have Narrow Moat - Discernible but modest moat.

Citius Pharmaceuticals  (STU:47N0) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Citius Pharmaceuticals Moat Score Related Terms

STU:47N0 vs LEXX, HIND, PTN: Moat Score Comparison

For the Biotechnology subindustry, Citius Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citius Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Citius Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Citius Pharmaceuticals's Moat Score falls into.


STU:47N0
25GF Score
Citius Pharmaceuticals Inc STU:47N0
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Citius Pharmaceuticals (STU:47N0) has a Moat Score of 4 as of Aug. 08, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Citius Pharmaceuticals ranks #156 out of 1393 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Citius Pharmaceuticals' Moat Score too high?
Citius Pharmaceuticals' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Citius Pharmaceuticals' value of 4 is 100% above this industry median. Based on the distribution chart, Citius Pharmaceuticals ranks #156 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Citius Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Citius Pharmaceuticals' Moat Score compare to LEXX and HIND?
According to the Biotechnology industry distribution chart, Citius Pharmaceuticals ranks #156 out of 1393 companies for Moat Score. This places Citius Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Citius Pharmaceuticals' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Citius Pharmaceuticals's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Pharmaceuticals's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Pharmaceuticals stock overvalued right now?
Citius Pharmaceuticals (STU:47N0) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Citius Pharmaceuticals' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Citius Pharmaceuticals (STU:47N0), the current Moat Score is 4 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Pharmaceuticals Business Description

Other Exchanges CTXR:USA
Address 11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
25GF Score

Get the complete analysis for STU:47N0

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.29
Price